Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study

Abstract

Data on prasugrel use in Japanese patients are limited to phase II/III clinical trials. This early postmarketing observational study evaluated the safety and efficacy of short-term prasugrel use in patients with acute coronary syndrome (ACS) in real-world clinical settings in Japan. From May 2014 to January 2015, we enrolled consecutive patients with ACS requiring percutaneous coronary intervention in each institution. Each patient started prasugrel treatment ≥1 month before the end of the study period. Safety outcomes included incidence rates of adverse drug reactions (ADRs) and bleeding adverse events (AEs). Efficacy outcomes were incidence rates of cardiovascular events (including major adverse cardiovascular events [MACE]). Case report forms were collected from 749 patients, 732 of whom were eligible for the safety and efficacy analysis sets. Approximately 95% of patients had a prasugrel loading/maintenance dose of 20 mg/3.75 mg/day. The incidences of ADRs and bleeding AEs were 8.6 and 6.4%, respectively. Twelve patients experienced major bleeding AEs; approximately 60% (seven patients) of which were gastrointestinal disorders. The incidence of bleeding AEs was significantly higher primarily in patients of female sex, aged ≥75 years, with low body weight (≤50 kg), severe cardiovascular disease, or severe renal impairment. The incidence of MACE was 1.9% during prasugrel treatment, and 3.1% at the end of the study period. This short-term study indicated that prasugrel treatment at loading/maintenance doses of 20 mg/3.75 mg/day was safe and effective in Japanese ACS patients in an acute setting.Clinical Trial Registration: This study is registered at http://www.umin.ac.jp/ctr/ under the identifier UMIN000014699.Electronic supplementary materialThe online version of this article (doi:10.1007/s12928-017-0459-8) contains supplementary material, which is available to authorized users.

Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapy

“…Both the bleeding risk and thrombotic risk were presented separately. Individual component of risk score had been reported previously and corresponded well to those identified by a post-marketing survey of prasugrel in Japan [32] ( Fig. 2).…”

“…Accumulation of factors sharply increased the bleeding risk. Reproduced, with permission, from Nakamura et al[32].…”

Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study

“…In addition, using the administrative database, this study focused mainly on patients exposed to drugs that inhibit gastric acid secretion, based on previous epidemiological research for stroke and bleeding events [45]. Although we adjusted for some confounding factors using the IPTW method in the subgroup analysis, other potential risk factors shown in the previous research (such as bleeding risk score) will need to be identified and collected in future research [46][47][48]. As the current study design does not permit accurate assessment of multiple outcomes (as each outcome requires consideration of a different profile of potential confounding factors in order to minimize bias), there is value in conducting future comparisons of vonoprazan and PPIs to assess their relative effect on medical costs (including hospitalization costs) related to gastrointestinal bleeding, cardiovascular outcomes, and mortality (which are critical endpoints for IHD patients, although their assessment will require a larger sample size), and complications associated with acid-suppressive drugs.…”

JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease

“…Moderate or severe ischemic stroke within the past 6 months. 5,36,49 The risk of ICH may be increased in Japanese patients taking aspirin.…”